Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.
Even a 5% erosion of search query share to ChatGPT, Perplexity, and other generative-AI entrants would compress Alphabet's earnings by roughly 12%. The risk is in the multiple, not the headline growth.
Grasberg's ramp-down, the Chinese smelter rebellion, the Grasberg Block Cave transition, and hyperscaler copper demand. Four signals, one direction.
Free cash flow crossed $7 billion in 2024 and is on track for $10 billion in 2025. The buyback programme is now meaningful enough to move EPS.
Both banks have rallied into earnings week. The valuation gap between them has tightened to a multi-year low. Which one is priced correctly?
Deere, Caterpillar and Honeywell all sit at the centre of the capex recovery story. Each offers a different exposure. Here is how to rank them.
Boeing announced Q1 deliveries and the defence business continues to quietly reset. The detail behind the number matters more than the number itself.
US commercial revenue crossed $500 million in Q4 2024 and is growing 55%+ year on year. The government-revenue concentration story is finally ending.
Zepbound supply has tripled since launch and is still constrained. The manufacturing footprint now represents one of the strongest competitive moats in large-cap pharma.
Uber ad revenue crossed $1.5 billion run-rate in late 2024, growing 70%+ year on year. The capital-light profit layer is bigger than our prior view assumed.
The Iran tension has lifted both names. The dividend sustainability question separates them.
UnitedHealth heads into earnings as the consensus expects a beat. The Medicare Advantage cost dynamic suggests the beat does not matter.
Operating margin expanded another 40 basis points in Q4 2024, driven by Walmart Connect advertising and marketplace fulfilment. Our prior thesis is validated and upgraded.
Goldman filed for a Bitcoin ETF targeting income this week. The filing is a smaller story than the capital allocation pattern behind it.
Nvidia just extended its win streak to 10 days. The charts explain why, and why the setup from here is more complicated than the headline implies.
Pfizer is three years into a reset that has reshaped the pipeline, the balance sheet, and the long-term earnings profile. The market still prices the old narrative.